Integrated Platform for Measuring and Reducing Symptoms of Autism Spectrum Disorder

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Autism Spectrum Disorder

In brief

This study will consist of a randomized, double-blind, sham-controlled clinical trial at SUNY Upstate Medical University and Mt. Sinai Medical Center with 80 autistic children evaluating the effects of transcranial photobiomodulation (tPBM) on multiple clinically validated scales.

Key facts

Study ID

NCT06006637

Run by

State University of New York - Upstate Medical University

People needed

80

Starts

2023-10-17

Expected to finish

2026-08-15

Last updated by the study team

2025-10-14

Who can join

Age: 2 and older, up to 8. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages 2 - 8
• Autism spectrum disorder diagnosis
• CARS-2 score of 30 - 45

You may not qualify if…

• CARS scores less than 30 or over 45.
• Taking psychotropic medications.
• Having skin lesions on scalp
• Having history of seizures
• Having history of abnormal EEG
• Being a relative of the PI or a researcher
• Having implanted devices (including cochlear implants).

Where it is running

• Mt. Sinai Medical Center — New York, New York, United States (enrolling)
• Golisano Center for Special Needs — Syracuse, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.